Serum Androgen Levels as a Marker for the Severity of Preeclampsia
NCT ID: NCT03744988
Last Updated: 2018-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
75 participants
OBSERVATIONAL
2017-10-01
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Androgens Level in the Third Trimester of Pregnancy in Patients With Preeclampsia
NCT02992145
The Association Between Different Markers With Development of Maternal and Neonatal Complications in Women With Severe Preeclampsia
NCT07125599
Assessment of Oxidative Stress Contents in Jordanian Pregnant Women With Preeclampsia
NCT07119034
Evaluation of Neutrophil/Lymphocyte Ratio ,Platelet/Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia
NCT03630276
Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia
NCT02699437
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypertensive disorders during pregnancy are classified into 4 categories, as recommended by the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy:
* Chronic hypertension
* Preeclampsia-eclampsia
* Preeclampsia superimposed on chronic hypertension
* Gestational hypertension (transient hypertension of pregnancy or chronic hypertension identified in the latter half of pregnancy). This terminology is preferred over the older but widely used term "pregnancy-induced hypertension" (PIH) because it is more precise .
In 2008, the Society of Obstetricians and Gynecologists of Canada (SOGC) released revised guidelines that simplified the classification of hypertension in pregnancy into 2 categories, preexisting or gestational, with the option to add "with preeclampsia" to either category if additional maternal or fetal symptoms, signs, or test results support this .
Chronic hypertension is defined as blood pressure exceeding 140/90 mm Hg before pregnancy or before 20 weeks' gestation. When hypertension is first identified during a woman's pregnancy and she is at less than 20 weeks' gestation, blood pressure elevations usually represent chronic hypertension.
In contrast, new onset of elevated blood pressure readings after 20 weeks' gestation mandates the consideration and exclusion of preeclampsia .
Chronic Hypertension Chronic hypertension is a primary disorder in 90-95% of cases and may be either essential (90%) or secondary to some identifiable underlying disorder, such as renal parenchymal disease (eg, polycystic kidneys, glomerular or interstitial disease), renal vascular disease (eg, renal artery stenosis, fibro-muscular dysplasia), endocrine disorders (eg, adreno-corticosteroid or mineralocorticoid excess, pheochromocytoma, hyperthyroidism or hypothyroidism, growth hormone excess, hyperparathyroidism), coarctation of the aorta, or oral contraceptive use. About 20-25% of women with chronic hypertension develop preeclampsia during pregnancy .
Chronic hypertension occurs in up to 22% of women of childbearing age, with the prevalence varying according to age, race, and body mass index. Population-based data indicate that approximately 1% of pregnancies are complicated by chronic hypertension, 5-6% by gestational hypertension without proteinuria, and 1-2% by preeclampsia .
Differential Diagnosis
* Antiphospholipid Antibody Syndrome and Pregnancy
* Antithrombin Deficiency
* Aortic Coarctation
* Autoimmune Thyroid Disease and Pregnancy
* Cardiomyopathy, Peri-partum
* Common Pregnancy Complaints and Questions
* Cushing Syndrome
* Diabetes Mellitus and Pregnancy
* Disseminated Intravascular Coagulation
* Eclampsia
* Encephalopathy, Hypertensive
* Fetal Growth Restriction
* Gastrointestinal Disease and Pregnancy
* Glomerulonephritis, Acute
* Glomerulonephritis, Chronic
* Graves' Disease
* Hashimoto Thyroiditis
* Hematologic Disease and Pregnancy
* Hemolytic-Uremic Syndrome
* Hydatidiform Mole
* Hyper-aldosteronism, Primary
* Hyperparathyroidism
* Hypertension
* Hypertension, Malignant
* Hyperthyroidism
* Hypothyroidism
* Nephrotic Syndrome
* Normal Labor and Delivery
* Preeclampsia
* Protein C Deficiency
* Protein S Deficiency
* Pulmonary Disease and Pregnancy
* Systemic Lupus Erythematosus
* Systemic Lupus Erythematosus and Pregnancy
* Teratology and Drug Use During Pregnancy
* Thrombotic Thrombocytopenic Purpura Gestational Hypertension Gestational hypertension refers to hypertension with onset in the latter part of pregnancy (\>20 weeks' gestation) without any other features of preeclampsia, and followed by normalization of the blood pressure postpartum. Of women who initially present with apparent gestational hypertension, about one third develops the syndrome of preeclampsia. As such, these patients should be observed carefully for this progression. The pathophysiology of gestational hypertension is unknown, but in the absence of features of preeclampsia, the maternal and fetal outcomes are usually normal .
Gestational hypertension may, however, be a harbinger of chronic hypertension later in life Furthermore, hypertension before pregnancy or during early pregnancy is associated with a twofold increased risk of gestational diabetes mellitus. Transient hypertension of pregnancy (ie, the development of isolated hypertension in a woman in late pregnancy without other manifestations of preeclampsia) is associated strongly with later development of chronic hypertension .
Although maternal diastolic blood pressure greater than 110 mm Hg is associated with an increased risk for placental abruption and fetal growth restriction, superimposed pre-eclamptic disorders cause most of the morbidity due to chronic hypertension during pregnancy .
Preeclampsia is defined as the new onset of hypertension and either proteinuria or end organ dysfunction after 20 weeks of gestation in a previously normotensive woman. In 2013, the American College of Obstetricians and Gynecologists removed proteinuria as an essential criterion for diagnosis of preeclampsia. They also removed massive proteinuria (5 grams/24hours) and fetal growth restriction as possible features of severe disease because massive proteinuria has a poor correlation with outcome and fetal growth restriction is managed similarly whether or not preeclampsia is diagnosed. Oliguria was also removed as a characteristic of severe disease.
Hypertension before 20 weeks' gestation is almost always due to chronic hypertension; new-onset or worsening hypertension after 20 weeks' gestation should lead to a careful evaluation for manifestations of preeclampsia .
Signs suggesting a secondary medical cause of chronic hypertension Centripetal obesity, "buffalo hump," and/or wide purple abdominal striae suggest glucocorticoid excess; other clinical signs may demonstrate hyperthyroidism, hypothyroidism, or growth hormone excess. In addition, a systolic bruit heard over the abdomen or in the flanks suggests renal artery stenosis, whereas radio femoral delay or diminished pulses in the lower versus upper extremities suggests coarctation of the aorta .
Women with chronic hypertension in pregnancy should be monitored for the development of worsening hypertension and/or the development of superimposed pre-eclampsia (the risk is approximately 25%). Laboratory investigations for pre-eclampsia should be repeated if the patient's blood pressure increases or if she develops signs or symptoms of preeclampsia .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
serum androgen levels will be measured in 25 normotensive pregnant women
serum androgen levels
measurement of serum free and total testosterone
mild preeclampsia
serum androgen levels will be measured in 25 mild preeclamptic patients
serum androgen levels
measurement of serum free and total testosterone
severe preeclampsia
serum androgen levels will be measured in 25 severe preeclamptic patients
serum androgen levels
measurement of serum free and total testosterone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
serum androgen levels
measurement of serum free and total testosterone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 20 and 35 years old.
* Live fetus.
Exclusion Criteria
* Intrauterine fetal death.
* History of pre-gestational hypertension.
* History of hormonal disorders (thyroid gland disorders and hyperprolactinemia).
* Smoker.
* Polycystic ovary syndrome.
* Signs or symptoms of hyper-androgenism (hirsutism, acne, oily skin, etc.).
* Diabetes mellitus.
* Drug use except ordinary supplementation (iron, folic acid).
20 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joseph Adel Ibrahiem Johny
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph A Ibrahiem, student
Role: PRINCIPAL_INVESTIGATOR
Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, , Egypt
AinShams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Joseph Adel Ibrahiem Johny
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.